A-485
Based on 110 publication(s) in Google Scholar
A-485, a chemical probe, is a potent and selective catalytic inhibitor of p300/CBP with IC50s of 9.8 nM and 2.6 nM for p300 and CBP histone acetyltransferase (HAT), respectively.
For research use only. We do not sell to patients.
- Purity: 99.87%
- CAS No.: 1889279-16-6
- Formula: C25H24F4N4O5
- Molecular Weight:536.48
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) A-485
More- Cancer Cell. 2026 Mar 19:S1535-6108(26)00111-X. [Abstract]
- Nature. 2023 Oct;622(7981):173-179. [Abstract]
- Cancer Cell. 2019 Dec 9;36(6):630-644.e9. [Abstract]
- Cell. 2026 Jun 11;189(12):3541-3552.e18. [Abstract]
- Cell. 2025 Oct 16;188(21):5878-5894.e18. [Abstract]
- Cell. 2025 May 29;188(11):2992-3012.e16. [Abstract]
- Nat Biotechnol. 2025 Nov 6. [Abstract]
- Immunity. 2024 Feb 13;57(2):364-378.e9. [Abstract]
- Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]
- Cancer Res. 2025 Aug 1;85(15):2838-2857. [Abstract]
- Nat Commun. 2026 Jun 15. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Nat Commun. 2025 Aug 29;16(1):8071. [Abstract]
- Nat Commun. 2025 Jul 17;16(1):6592. [Abstract]
- Nat Commun. 2025 Jan 16;16(1):710. [Abstract]
- Nat Commun. 2023 Jul 14;14(1):4129. [Abstract]
- Nat Commun. 2021 Sep 20;12(1):5548. [Abstract]
- Redox Biol. 2025 Oct:86:103834. [Abstract]
- Mol Cell. 2023 Jul 20;83(14):2398-2416.e12. [Abstract]
- Nucleic Acids Res. 2025 Aug 27;53(16):gkaf841. [Abstract]
- Theranostics. 2024 Jul 8;14(11):4297-4317. [Abstract]
- Theranostics. 2021 Jan 1;11(3):1473-1492. [Abstract]
- J Biomed Sci. 2025 Jul 6;32(1):61. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(23):e18185. [Abstract]
- Adv Sci (Weinh). 2025 Dec 22:e13400. [Abstract]
- Adv Sci (Weinh). 2025 Jul 11:e02402. [Abstract]
- Adv Sci (Weinh). 2025 May;12(20):e2413709. [Abstract]
- Adv Sci (Weinh). 2024 Oct;11(38):e2406333. [Abstract]
- Adv Sci (Weinh). 2024 May;11(19):e2308031. [Abstract]
- Sci Adv. 2023 Oct 6;9(40):eadi8343. [Abstract]
- Cell Death Differ. 2026 May 25. [Abstract]
- Chem Eng J. 2021, 130806.
- Cell Mol Biol Lett. 2026 Mar 9;31(1):31. [Abstract]
- Cell Death Dis. 2025 Jun 3;16(1):432. [Abstract]
- Cell Death Dis. 2021 May 12;12(5):476. [Abstract]
- Cell Death Dis. 2020 Sep 11;11(9):745. [Abstract]
- J Exp Med. 2025 May 5;222(5):e20241184. [Abstract]
- Acta Pharmacol Sin. 2025 Jun 11. [Abstract]
- Cell Death Discov. 2024 May 1;10(1):206. [Abstract]
- Acta Pharmacol Sin. 2022 Feb;43(2):457-469. [Abstract]
- Proc Natl Acad Sci U S A. 2026 Mar 10;123(10):e2525274123. [Abstract]
- Cell Chem Biol. 2021 Apr 15;28(4):503-514.e12. [Abstract]
- JHEP Rep. 2026 May 27:101903. [Abstract]
- Int J Biol Macromol. 2025 Aug 5;322(Pt 1):146571. [Abstract]
- EMBO J. 2025 Aug 20. [Abstract]
- EMBO J. 2022 Apr 19;41(8):e109463. [Abstract]
- Mol Med. 2025 Dec 16;31(1):336. [Abstract]
- Free Radic Biol Med. 2025 Oct:238:430-449. [Abstract]
- Free Radic Biol Med. 2025 Apr 30:S0891-5849(25)00272-2. [Abstract]
- Cell Rep. 2026 Jun 2;45(6).
- Cell Rep. 2026 Mar 15;45(3):117084. [Abstract]
- Cell Rep. 2026 Jan 30;45(2):116929. [Abstract]
- Cell Rep. 2025 Jul 30;44(8):116091. [Abstract]
- Cell Rep. 2024 Nov 26;43(12):115015. [Abstract]
- Aging Cell. 2024 Nov;23(11):e14284. [Abstract]
- Cell Rep. 2023 Dec 13;42(12):113564. [Abstract]
- Cell Rep. 2021 Nov 9;37(6):109988. [Abstract]
- Br J Pharmacol. 2026 Apr 29. [Abstract]
- Cell Syst. 2025 Aug 20;16(8):101346. [Abstract]
- J Invest Dermatol. 2025 Feb;145(2):411-422.e7. [Abstract]
- J Invest Dermatol. 2023 Mar;143(3):431-443.e19. [Abstract]
- JCI Insight. 2022 Jan 11;7(1):e141344. [Abstract]
- Biochem Pharmacol. 2025 Jun:236:116901. [Abstract]
- J Bone Miner Res. 2023 Dec;38(12):1885-1899. [Abstract]
- Liver Int. 2023 Aug;43(8):1729-1740. [Abstract]
- EMBO Rep. 2025 Jun;26(12):3106-3137. [Abstract]
- Stem Cells Transl Med. 2024 Feb 14;13(2):151-165. [Abstract]
- Commun Biol. 2025 Nov 20;8(1):1626. [Abstract]
- Int Immunopharmacol. 2026 Feb 1:170:116125. [Abstract]
- Int J Mol Sci. 2024 Dec 31;26(1):271. [Abstract]
- Int J Mol Sci. 2023 Apr 11;24(8):7031. [Abstract]
- Int Immunopharmacol. 2021 May:94:107458. [Abstract]
- Phenomics. 2026 Jun 10.
- Biol Direct. 2024 Jun 21;19(1):48. [Abstract]
- Biol Res. 2025 May 29;58(1):30. [Abstract]
- Toxicology. 2025 Jun:514:154109. [Abstract]
- PLoS Pathog. 2023 Feb 24;19(2):e1011202. [Abstract]
- PLoS Pathog. 2023 Feb 22;19(2):e1011189. [Abstract]
- Cancers (Basel). 2024 Jan 21;16(2):457. [Abstract]
- Cancers (Basel). 2020 Dec 21;12(12):3867. [Abstract]
- Cell Signal. 2024 Jul:119:111170. [Abstract]
- Brain Res Bull. 2026 Feb:235:111744. [Abstract]
- iScience. 2024 Aug 21;27(9):110775. [Abstract]
- ACS Chem Neurosci. 2021 Jul 7;12(13):2273-2279. [Abstract]
- BMC Cancer. 2025 May 28;25(1):955. [Abstract]
- Pathogens. 2023 Jun 15;12(6):831. [Abstract]
- Cancer Med. 2026 Jun;15(6):e71985. [Abstract]
- Exp Cell Res. 2022 Nov 1;420(1):113336. [Abstract]
- Tissue Cell. 2023 Feb:80:101964. [Abstract]
- Mol Biol Cell. 2024 Jun 1;35(6):ar88. [Abstract]
- Insects. 2023 Mar 23;14(4):309. [Abstract]
- Biochem Biophys Res Commun. 2024 Jul 12:717:150061. [Abstract]
- Biochem Biophys Res Commun. 2021 Sep 16;578:77-83. [Abstract]
- Biomed Chromatogr. 2024 Apr;38(4):e5819. [Abstract]
- University of North Carolina at Chapel Hill. 2026.
- bioRxiv. 2026 May 26:2026.05.22.726988. [Abstract]
- bioRxiv. 2026 Apr 4:2026.04.03.716381. [Abstract]
- bioRxiv. 2026 Feb 13:2026.02.12.705659. [Abstract]
- bioRxiv. 2026 Jan 14.
- bioRxiv. 2025 Nov 3:2025.11.02.686178. [Abstract]
- bioRxiv. 2025 May 13:2025.05.07.652677. [Abstract]
- bioRxiv. 2025 Apr 28:2025.04.28.651040. [Abstract]
- Environ Toxicol. 2025 Jan;40(1):140-151. [Abstract]
- bioRxiv. 2024 Dec 23:2024.12.23.630174. [Abstract]
- bioRxiv. 2024 July 27.
- Chemrxiv. 2024 Mar 26.
- bioRxiv. 2024 Feb 7.
- bioRxiv. 2024 Feb 16.
- Biomed Pharmacother. 2023 Apr:160:114402. [Abstract]
- Research Square Preprint. 2023 Apr 11.
-
Cell Proliferation/Viability Assay
-
WB
-
WB
-
RT-PCR
-
IF
Biological Activity
|
CBP/p300 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 4T1 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| A-375 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human A-375 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| AMO1 | EC50 |
1.09 μM
Compound: A-485
|
Antiproliferative activity against human AMO1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human AMO1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| BJAB | EC50 |
0.28 μM
Compound: A-485
|
Antiproliferative activity against human BJAB cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human BJAB cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| BT-20 | EC50 |
0.34 μM
Compound: A-485
|
Antiproliferative activity against human BT-20 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human BT-20 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| CA46 | EC50 |
0.48 μM
Compound: A-485
|
Antiproliferative activity against human CA46 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human CA46 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| CAL-120 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human CAL-120 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human CAL-120 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Calu-6 | EC50 |
8.57 μM
Compound: A-485
|
Antiproliferative activity against human Calu-6 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Calu-6 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| CHL-1 | EC50 |
0.37 μM
Compound: A-485
|
Antiproliferative activity against human CHL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human CHL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| COLO-679 | EC50 |
2.26 μM
Compound: A-485
|
Antiproliferative activity against human COLO-679 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human COLO-679 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| COR-L47 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human COR-L47 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human COR-L47 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| CWR22R | EC50 |
0.32 μM
Compound: A-485
|
Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human 22Rv1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| CWR22R | IC50 |
490 nM
Compound: A-485
|
Antiproliferative activity against human 22Rv1 cells measured after 3 days by celltiter-glo luminescence assay
Antiproliferative activity against human 22Rv1 cells measured after 3 days by celltiter-glo luminescence assay
|
[PMID: 31910017] |
| Daudi | EC50 |
0.43 μM
Compound: A-485
|
Antiproliferative activity against human Daudi cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Daudi cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| DB | EC50 |
0.77 μM
Compound: A-485
|
Antiproliferative activity against human DB cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human DB cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| DOHH-2 | EC50 |
0.75 μM
Compound: A-485
|
Antiproliferative activity against human DOHH-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human DOHH-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| DU-145 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human DU-145 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human DU-145 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| DU-4475 | EC50 |
0.67 μM
Compound: A-485
|
Antiproliferative activity against human DU-4475 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human DU-4475 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| EMT6 | EC50 |
0.5 μM
Compound: A-485
|
Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against mouse EMT6 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| EOL1 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human EOL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human EOL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Farage | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human Farage cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Farage cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| G-361 | EC50 |
3.77 μM
Compound: A-485
|
Antiproliferative activity against human G361 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human G361 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| GA-10 | EC50 |
1.06 μM
Compound: A-485
|
Antiproliferative activity against human GA-10 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human GA-10 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Granta-519 | EC50 |
3.28 μM
Compound: A-485
|
Antiproliferative activity against human Granta-519 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Granta-519 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HCC1143 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human HCC1143 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HCC1143 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HCC1187 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human HCC1187 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HCC1187 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HCC1395 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human HCC1395 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HCC1395 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HCC1599 | EC50 |
4.85 μM
Compound: A-485
|
Antiproliferative activity against human HCC1599 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HCC1599 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HCC1806 | EC50 |
2.95 μM
Compound: A-485
|
Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HCC1806 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HCC1937 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human HCC1937 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HCC1937 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HCC2935 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human HCC2935 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HCC2935 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HCC38 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human HCC38 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HCC38 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HCC4006 | EC50 |
4.64 μM
Compound: A-485
|
Antiproliferative activity against human HCC4006 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HCC4006 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HCC70 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human HCC70 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HCC70 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HEL | EC50 |
3.09 μM
Compound: A-485
|
Antiproliferative activity against human HEL cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HEL cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HL-60 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HL-60 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Hs 294T | EC50 |
9 μM
Compound: A-485
|
Antiproliferative activity against human Hs294T cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Hs294T cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Hs 695T | EC50 |
3.57 μM
Compound: A-485
|
Antiproliferative activity against human Hs 695T cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Hs 695T cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HT | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human HT cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HT cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| HT-144 | EC50 |
3.08 μM
Compound: A-485
|
Antiproliferative activity against human HT-144 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human HT-144 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Jurkat | EC50 |
4.03 μM
Compound: A-485
|
Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| JVM-2 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human JVM-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human JVM-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| K562 | EC50 |
1.27 μM
Compound: A-485
|
Antiproliferative activity against human K562 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human K562 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| K562 | IC50 |
457 nM
Compound: A-485
|
Antiproliferative activity against human K562 cells measured after 3 days by celltiter-glo luminescence assay
Antiproliferative activity against human K562 cells measured after 3 days by celltiter-glo luminescence assay
|
[PMID: 31910017] |
| Karpas-1106P | EC50 |
0.41 μM
Compound: A-485
|
Antiproliferative activity against human KARPAS-1106P cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human KARPAS-1106P cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| KARPAS-299 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human KARPAS-299 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| KARPAS-422 | EC50 |
0.25 μM
Compound: A-485
|
Antiproliferative activity against human KARPAS-422 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human KARPAS-422 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Kasumi 1 | EC50 |
0.29 μM
Compound: A-485
|
Antiproliferative activity against human Kasumi 1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Kasumi 1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Kasumi 1 | EC50 |
0.33 μM
Compound: A-485
|
Antiproliferative activity against human Kasumi-1 cells assessed as reduction in cell viability incubated for 5 days by XTT assay
Antiproliferative activity against human Kasumi-1 cells assessed as reduction in cell viability incubated for 5 days by XTT assay
|
[PMID: 32314924] |
| Kasumi 1 | IC50 |
607.9 nM
Compound: A-485
|
Antiproliferative activity against human Kasumi-1 cells measured after 3 days by celltiter-glo luminescence assay
Antiproliferative activity against human Kasumi-1 cells measured after 3 days by celltiter-glo luminescence assay
|
[PMID: 31910017] |
| KMS-11 | EC50 |
0.24 μM
Compound: A-485
|
Antiproliferative activity against human KMS-11 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human KMS-11 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| L-363 | EC50 |
0.51 μM
Compound: A-485
|
Antiproliferative activity against human L-363 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human L-363 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| LNCaP | EC50 |
0.26 μM
Compound: A-485
|
Antiproliferative activity against human LNCaP cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human LNCaP cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay
|
[PMID: 35512565] |
| LNCaP | EC50 |
446 nM
Compound: 1; A-485
|
Antiproliferative activity against human LNCAP cells
Antiproliferative activity against human LNCAP cells
|
[PMID: 33631370] |
| LNCaP | IC50 |
1.7 μM
Compound: A485
|
Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human LNCaP cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38215590] |
| LNCaP-Clone-FGC | EC50 |
0.26 μM
Compound: A-485
|
Antiproliferative activity against human LNCaP-Clone-FGC cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human LNCaP-Clone-FGC cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| LNCaP-Clone-FGC | EC50 |
0.35 μM
Compound: 1; A-485
|
Antiproliferative activity against AR-positive human LNCaP-Clone-FGC cells assessed as inhibition of cell proliferation measured after 5 days by luminiscent plate reader method
Antiproliferative activity against AR-positive human LNCaP-Clone-FGC cells assessed as inhibition of cell proliferation measured after 5 days by luminiscent plate reader method
|
[PMID: 34055218] |
| LNCaP-Clone-FGC | IC50 |
215 nM
Compound: A-485
|
Antiproliferative activity against human LNCaP-FGC cells measured after 5 days by celltiter-glo luminescence assay
Antiproliferative activity against human LNCaP-FGC cells measured after 5 days by celltiter-glo luminescence assay
|
[PMID: 31910017] |
| Malme-3M | EC50 |
2.69 μM
Compound: A-485
|
Antiproliferative activity against human Malme-3M cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Malme-3M cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Maver1 | IC50 |
226.1 nM
Compound: A-485
|
Antiproliferative activity against human Maver1 cells measured after 3 days by celltiter-glo luminescence assay
Antiproliferative activity against human Maver1 cells measured after 3 days by celltiter-glo luminescence assay
|
[PMID: 31910017] |
| MCF7 | EC50 |
>30 μM
Compound: A-485
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 6 days by Celigo-insitu cell cytometer analysis
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 6 days by Celigo-insitu cell cytometer analysis
|
[PMID: 32314924] |
| MCF7 | EC50 |
>30 μM
Compound: A-485
|
Antiproliferative activity against human tamoxifen-resistant MCF7 cells assessed as reduction in cell viability incubated for 6 days by Celigo-insitu cell cytometer analysis
Antiproliferative activity against human tamoxifen-resistant MCF7 cells assessed as reduction in cell viability incubated for 6 days by Celigo-insitu cell cytometer analysis
|
[PMID: 32314924] |
| MCF7 | IC50 |
>30 μM
Compound: A485
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38215590] |
| MDA-MB-157 | EC50 |
4.59 μM
Compound: A-485
|
Antiproliferative activity against human MDA-MB-157 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human MDA-MB-157 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| MDA-MB-231 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay
|
[PMID: 35512565] |
| MDA-MB-231 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| MDA-MB-436 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| MDA-MB-453 | EC50 |
1.87 μM
Compound: A-485
|
Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human MDA-MB-453 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| MDA-MB-468 | EC50 |
0.38 μM
Compound: A-485
|
Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| MeWo | EC50 |
2.43 μM
Compound: A-485
|
Antiproliferative activity against human MeWo cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human MeWo cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| MM1.S | EC50 |
0.18 μM
Compound: A-485
|
Antiproliferative activity against human MM1.S cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human MM1.S cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| MM1.S | EC50 |
139 nM
Compound: A-485
|
Antiproliferative activity against human MM1.S cells assessed as reduction in cell proliferation incubated for 72 hrs by MTS assay
Antiproliferative activity against human MM1.S cells assessed as reduction in cell proliferation incubated for 72 hrs by MTS assay
|
[PMID: 35814928] |
| MOLM-13 | EC50 |
0.35 μM
Compound: A-485
|
Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human MOLM-13 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay
|
[PMID: 35512565] |
| MOLM-13 | EC50 |
0.35 μM
Compound: A-485
|
Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| MOLT-4 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| MV4-11 | IC50 |
255.2 nM
Compound: A-485
|
Antiproliferative activity against human MV4-11 cells measured after 3 days by celltiter-glo luminescence assay
Antiproliferative activity against human MV4-11 cells measured after 3 days by celltiter-glo luminescence assay
|
[PMID: 31910017] |
| NCI-H1048 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H1048 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H1048 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H128 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H128 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H128 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H1373 | EC50 |
2.34 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H1373 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H1373 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H1417 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H1417 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H1417 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H146 | EC50 |
0.4 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H146 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H146 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H1693 | EC50 |
2.37 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H1693 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H1693 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H1836 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H1836 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H1836 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H187 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H187 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H187 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H1930 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H1930 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H1930 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H2081 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H2081 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H2081 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H209 | EC50 |
0.4 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H209 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H209 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H211 | EC50 |
1.5 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H211 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H211 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H23 | EC50 |
1.79 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H23 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H23 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H2444 | EC50 |
5.92 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H2444 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H2444 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H441 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H441 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H441 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H510A | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H510A cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H510A cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H522 | EC50 |
3.52 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H522 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H522 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H596 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H596 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H596 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H661 | EC50 |
7.66 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H69 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H69 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H69 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H727 | EC50 |
6.63 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H727 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H727 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H838 | EC50 |
6.99 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H838 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H838 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NCI-H929 | EC50 |
0.33 μM
Compound: A-485
|
Antiproliferative activity against human NCI-H929 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NCI-H929 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NU-DHL-1 | EC50 |
0.53 μM
Compound: A-485
|
Antiproliferative activity against human NU-DHL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NU-DHL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| NU-DUL-1 | EC50 |
0.48 μM
Compound: A-485
|
Antiproliferative activity against human NU-DUL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human NU-DUL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| OCI-AML2 | EC50 |
2.03 μM
Compound: A-485
|
Antiproliferative activity against human OCI-AML2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human OCI-AML2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| OCI-AML-5 | EC50 |
4.86 μM
Compound: A-485
|
Antiproliferative activity against human OCI-AML5 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human OCI-AML5 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| OCI-Ly1 | EC50 |
0.94 μM
Compound: A-485
|
Antiproliferative activity against human OCI-Ly1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human OCI-Ly1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| OCI-Ly18 | EC50 |
0.32 μM
Compound: A-485
|
Antiproliferative activity against human OCI-Ly18 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human OCI-Ly18 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| OCI-Ly3 | EC50 |
0.49 μM
Compound: A-485
|
Antiproliferative activity against human OCILY3 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human OCILY3 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| OCI-Ly7 | EC50 |
1.81 μM
Compound: A-485
|
Antiproliferative activity against human OCILY7 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human OCILY7 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| OPM-2 | EC50 |
0.62 μM
Compound: A-485
|
Antiproliferative activity against human OPM-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human OPM-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| OVCAR-3 | EC50 |
5.44 μM
Compound: A-485
|
Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 120 hrs by Cell-titre glo assay
Antiproliferative activity against human OVCAR-3 cells assessed as inhibition of cell proliferation measured after 120 hrs by Cell-titre glo assay
|
[PMID: 34801827] |
| PANC-1 | EC50 |
>30 μM
Compound: A-485
|
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
|
[PMID: 32314924] |
| PANC-1 | IC50 |
>30 μM
Compound: A485
|
Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay
|
[PMID: 38215590] |
| PC-3 | EC50 |
2.05 μM
Compound: A-485
|
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| PC-3 | EC50 |
2.1 μM
Compound: A-485
|
Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay
|
[PMID: 35512565] |
| Pfeiffer | EC50 |
0.86 μM
Compound: A-485
|
Antiproliferative activity against human Pfeiffer cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Pfeiffer cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Raji | EC50 |
0.46 μM
Compound: A-485
|
Antiproliferative activity against human Raji cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Raji cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Ramos | EC50 |
0.93 μM
Compound: A-485
|
Antiproliferative activity against human Ramos cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Ramos cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| RCK8 | EC50 |
0.59 μM
Compound: A-485
|
Antiproliferative activity against human RCK8 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human RCK8 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Rec1 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human REC1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human REC1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| RL | EC50 |
1.05 μM
Compound: A-485
|
Antiproliferative activity against human RL cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human RL cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| RPMI-8226 | EC50 |
0.16 μM
Compound: A-485
|
Antiproliferative activity against human RPMI-8226 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay
Antiproliferative activity against human RPMI-8226 cells assessed as reduction in cell growth incubated for 3 to 5 days by CellTiter-Glo luminescent cell viability assay
|
[PMID: 35512565] |
| RPMI-8226 | EC50 |
0.16 μM
Compound: A-485
|
Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| SET-2 | EC50 |
2.01 μM
Compound: A-485
|
Antiproliferative activity against human SET2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human SET2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Sf9 | IC50 |
0.06 μM
Compound: A-485
|
Inhibition of recombinant human N-terminal 6His-FLAG-tagged p300 BHC domain (1036 to 1822 residues) expressed in baculovirus infected Sf9 insect cells using biotinylated-histone H4 peptide as substrate preincubated for 30 mins followed by substrate additi
Inhibition of recombinant human N-terminal 6His-FLAG-tagged p300 BHC domain (1036 to 1822 residues) expressed in baculovirus infected Sf9 insect cells using biotinylated-histone H4 peptide as substrate preincubated for 30 mins followed by substrate additi
|
[PMID: 31910017] |
| SKM-1 | EC50 |
1.34 μM
Compound: A-485
|
Antiproliferative activity against human SKM-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human SKM-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| SK-MEL-1 | EC50 |
0.57 μM
Compound: A-485
|
Antiproliferative activity against human SK-MEL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human SK-MEL-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| SK-MEL-2 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human SK-MEL-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human SK-MEL-2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| SK-MEL-24 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human SK-MEL-24 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human SK-MEL-24 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| SK-MEL-5 | EC50 |
0.91 μM
Compound: A-485
|
Antiproliferative activity against human SK-MEL-5 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human SK-MEL-5 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| SUD4 | EC50 |
0.72 μM
Compound: A-485
|
Antiproliferative activity against human SU-DHL-4 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human SU-DHL-4 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| SU-DHL10 | EC50 |
0.92 μM
Compound: A-485
|
Antiproliferative activity against human Su-DHL-10 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Su-DHL-10 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| SU-DHL-16 | EC50 |
0.73 μM
Compound: A-485
|
Antiproliferative activity against human SU-DHL-16 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human SU-DHL-16 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| SU-DHL-2 | EC50 |
0.95 μM
Compound: A-485
|
Antiproliferative activity against human SUDHL2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human SUDHL2 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| SU-DHL-5 | EC50 |
0.76 μM
Compound: A-485
|
Antiproliferative activity against human SuDHL5 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human SuDHL5 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| SU-DHL-6 | EC50 |
0.75 μM
Compound: A-485
|
Antiproliferative activity against human SU-DHL-6 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human SU-DHL-6 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| SU-DHL-8 | EC50 |
0.54 μM
Compound: A-485
|
Antiproliferative activity against human SU-DHL-8 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human SU-DHL-8 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| THP-1 | EC50 |
3.51 μM
Compound: A-485
|
Antiproliferative activity against human THP-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human THP-1 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| Toledo | EC50 |
0.49 μM
Compound: A-485
|
Antiproliferative activity against human Toledo cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human Toledo cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| U2932 | EC50 |
2.46 μM
Compound: A-485
|
Antiproliferative activity against human U2932 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human U2932 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| U-2940 | EC50 |
1.33 μM
Compound: A-485
|
Antiproliferative activity against human U-2940 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human U-2940 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| U-2973 | EC50 |
0.66 μM
Compound: A-485
|
Antiproliferative activity against human U-2973 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human U-2973 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| U-937 | EC50 |
>10 μM
Compound: A-485
|
Antiproliferative activity against human U937 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human U937 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| ULA | EC50 |
0.55 μM
Compound: A-485
|
Antiproliferative activity against human ULA cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human ULA cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| VCaP | EC50 |
0.04 μM
Compound: A-485
|
Antiproliferative activity against human VCaP cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human VCaP cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| WM 266-4 | EC50 |
1.91 μM
Compound: A-485
|
Antiproliferative activity against human WM266-4 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human WM266-4 cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
| WSU-NHL | EC50 |
1.06 μM
Compound: A-485
|
Antiproliferative activity against human WSU-NHL cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
Antiproliferative activity against human WSU-NHL cells assessed as inhibition of cell viability incubated for 3 to 5 days by Celltiter-Glo luminescent assay
|
[PMID: 28953875] |
A three-hour treatment of prostate adenocarcinoma PC-3 cells with A-485 results in a dose-dependent decrease in H3K27Ac, with a half maximal effective concentration (EC50) of 73 nM. Treatment with A-485 does not alter p300 or CBP protein levels.The broadest sensitivity is observed in haematological tumours, where A-485 exhibits potent activity in most multiple myeloma cell lines, and in a subset of acute myeloid leukaemia lines and non-Hodgkin’s lymphoma lines. A-485 induces a comparable decrease in H3K27Ac in all five prostate cancer cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1889279-16-6
-
Appearance Solid
-
Molecular Weight 536.48
-
Formula C25H24F4N4O5
-
Color White to off-white
-
SMILES
O=C(N1CC(N([C@@H](C)C(F)(F)F)CC2=CC=C(F)C=C2)=O)[C@]3(OC1=O)C4=CC=C(NC(NC)=O)C=C4CC3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (110)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. [Abstract]2026 Mar 19:S1535-6108(26)00111-X. PMID: 41875889 -
Nature
2023 Oct;622(7981):173-179. PMID: 37731000
A-485 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Oct;622(7981):173-179. [Abstract]
Representative western blots of two biological replicates of HEK293T histones treated with A-485 and NU9056 (10 μM for 24 hours)
A-485 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Oct;622(7981):173-179. [Abstract]
Kacme (top) and H3K27ac (bottom) ChIP-qPCR in HEK293T cells after A-485 treatment (10 μM for 24 hours).
A-485 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Oct;622(7981):173-179. [Abstract]
qPCR results showing relative expression levels of indicated transcripts in HEK293T cells after A-485 treatment (10 μM for 24 hours).
A-485 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Oct;622(7981):173-179. [Abstract]
Quantifications of Transwell assays in indicated PANC-1 cells treated with different concentrations of A-485 (1.25-5 μM)
-
Cancer Cell
The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability. [Abstract]2019 Dec 9;36(6):630-644.e9. PMID: 31735627
A-485 purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2019 Dec 9;36(6):630-644.e9. [Abstract]
Western blot of MYC in PDX (11a) cells after ex vivo treatment with A-485 (0.1-1 μM) for 6 h.
-
Cell
2026 Jun 11;189(12):3541-3552.e18. PMID: 41999746 -
Cell
Composite transposons with bivalent histone marks function as RNA-dependent enhancers in cell fate regulation. [Abstract]2025 Oct 16;188(21):5878-5894.e18. PMID: 40774253 -
Cell
Long-term histone lactylation connects metabolic and epigenetic rewiring in innate immune memory. [Abstract]2025 May 29;188(11):2992-3012.e16. PMID: 40318634
A-485 purchased from MedChemExpress. Usage Cited in: Cell. 2025 May 29;188(11):2992-3012.e16. [Abstract]
Human monocytes were stimulated with BCG, LPS (1 ng/mL or indicated concentrations), or cultured in medium (RPMI) ± the indicated concentrations of A-485 (p300i, 1 μM) for 24 h. An MTT assay is used to assess the cellular viability (n = 6 donors, mean ± SEM).
-
Nat Biotechnol
CRISPR live-cell imaging reveals chromatin dynamics and enhancer interactions at multiple non-repetitive loci. [Abstract]2025 Nov 6. PMID: 41199023 -
Immunity
Small-molecule CBP/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response. [Abstract]2024 Feb 13;57(2):364-378.e9. PMID: 38301651 -
Nat Immunol
Ammonia detoxification promotes CD8+ T cell memory development by urea and citrulline cycles. [Abstract]2023 Jan;24(1):162-173. PMID: 36471170
A-485 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]
A485 (10 μM; 24 h) leads to the downregulation of H3K9bhb and CPS1 in BHB-treated CD8+ TM cells; however, the use of 3-TYP (10 μM; 24 h) or Trichostatin A (TSA; 5 nM; 24 h) result in the increase of H3K9bhb and CPS1.
A-485 purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]
TM cells (IL-15-derived) were treated with 3TY (10 μM), TSA (5 nM), A-485 (10 μM) or BHB (5 mM) for 24 h, then Cps1 mRNA was detected by qPCR.
-
Cancer Res
Tobacco Smoking Rewires Cell Metabolism by Inducing GAPDH Succinylation to Promote Lung Cancer Progression. [Abstract]2025 Aug 1;85(15):2838-2857. PMID: 40366632
A-485 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Aug 1;85(15):2838-2857. [Abstract]
A-485 (2 μM; 24 h) suppresses the ascending tendency of GAPDH K251-Su (0.5-6 μM; 24 h) induced by glutamine in NSCLC cells.
-
Nat Commun
SMARCA4 loss reprograms p300 chromatin occupancy to subvert p53-mediated transcriptional repression in ovarian small cell carcinoma. [Abstract]2026 Jun 15. PMID: 42297809 -
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Nat Commun
2025 Aug 29;16(1):8071. PMID: 40877321
A-485 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 29;16(1):8071. [Abstract]
A-485 (0.5-8 μM; 24 h) can partially reverse the lysine acetylation induced by wild-type MCP-p300Core.
-
Nat Commun
β-Hydroxybutyrate promotes cancer metastasis through β-hydroxybutyrylation-dependent stabilization of Snail. [Abstract]2025 Jul 17;16(1):6592. PMID: 40675949 -
Nat Commun
2025 Jan 16;16(1):710. PMID: 39814710
A-485 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 16;16(1):710. [Abstract]
A-485 (2.6 and 9.8 nM; 8.5 h) reduces the expression of TRIM43 in HFF1 cells infected with HSV-1 (HSV-1 GFP, MOI 3) (8 h), while the expression of ICP0 and ICP27 remains unchanged.
-
Nat Commun
2023 Jul 14;14(1):4129. PMID: 37452018
A-485 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Jul 14;14(1):4129. [Abstract]
A-485 is a potent Histone acetyltransferase (HAT) inhibitor. Quantification analysis using RT-qPCR shows that Rax and Six3 expression in day 5 cultures are significantly reduced by the addition of A-485 (2 µM) from day 4. Pan-neural marker Sox2 does not show significant change.
-
Nat Commun
Isonicotinylation is a histone mark induced by the anti-tuberculosis first-line drug isoniazid. [Abstract]2021 Sep 20;12(1):5548. PMID: 34545082 -
Redox Biol
Oxidative stress-induced ZEB1 acetylation drives a hybrid epithelial-mesenchymal phenotype and promotes lung metastasis in triple-negative breast cancer. [Abstract]2025 Oct:86:103834. PMID: 40850192 -
Mol Cell
Chromatin regulation of transcriptional enhancers and cell fate by the Sotos syndrome gene NSD1. [Abstract]2023 Jul 20;83(14):2398-2416.e12. PMID: 37402365 -
Nucleic Acids Res
SMAD3 and p300 complex scaffolding by long non-coding RNA LIMD1-AS1 promotes TGF-β-induced breast cancer cell plasticity. [Abstract]2025 Aug 27;53(16):gkaf841. PMID: 40889156 -
Theranostics
Astrocyte-derived lactate aggravates brain injury of ischemic stroke in mice by promoting the formation of protein lactylation. [Abstract]2024 Jul 8;14(11):4297-4317. PMID: 39113798 -
Theranostics
H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts. [Abstract]2021 Jan 1;11(3):1473-1492. PMID: 33391546 -
J Biomed Sci
Cardiac-specific overexpression of PRMT5 exacerbates pressure overload-induced hypertrophy and heart failure. [Abstract]2025 Jul 6;32(1):61. PMID: 40619438 -
Adv Sci (Weinh)
Identification of A p300-SP1-BRD4 Transcriptional Axis as a Key Driver of AR Hyperactivation in Polycystic Ovarian Syndrome. [Abstract]2026 Apr;13(23):e18185. PMID: 41684293 -
Adv Sci (Weinh)
Flipping the Switch: MeCP2-Mediated Lactylation Rewires Microglial Metabolism and Inflammation via the HK2/mTOR Axis in Poststroke Neuroinflammation. [Abstract]2025 Dec 22:e13400. PMID: 41429663 -
Adv Sci (Weinh)
Abnormal β-Hydroxybutyrylation Modification of ARG1 Drives Reprogramming of Arginine Metabolism to Promote the Progression of Colorectal Cancer. [Abstract]2025 Jul 11:e02402. PMID: 40641413 -
Adv Sci (Weinh)
UGDH Lactylation Aggravates Osteoarthritis by Suppressing Glycosaminoglycan Synthesis and Orchestrating Nucleocytoplasmic Transport to Activate MAPK Signaling. [Abstract]2025 May;12(20):e2413709. PMID: 40150862
A-485 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 May;12(20):e2413709. [Abstract]
Immunofluorescence staining of Collagen II and Aggrecan in chondrocytes with A485 (0,5,10,20 μM) treatment in the presence of IL-1β. Scale bar, 25 μm.
A-485 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 May;12(20):e2413709. [Abstract]
IHC of Collagen II, Aggrecan, MMP3 and MMP13 of articular cartilage in sham, DMM induced OA mice with A485 (articular injections of 2 µL, 20 mM at 1, 3, 5, and 7 W) or DMSO. (n=8 per group). Scale bars, 50 μm.
-
Adv Sci (Weinh)
Lactylated Apolipoprotein C-II Induces Immunotherapy Resistance by Promoting Extracellular Lipolysis. [Abstract]2024 Oct;11(38):e2406333. PMID: 38981044 -
Adv Sci (Weinh)
YY1 Lactylation Aggravates Autoimmune Uveitis by Enhancing Microglial Functions via Inflammatory Genes. [Abstract]2024 May;11(19):e2308031. PMID: 38493498 -
Sci Adv
Deficient chaperone-mediated autophagy facilitates LPS-induced microglial activation via regulation of the p300/NF-κB/NLRP3 pathway. [Abstract]2023 Oct 6;9(40):eadi8343. PMID: 37801503 -
Cell Death Differ
Targeting ADAR1 lactylation activates innate immune and overcomes chemoresistance in ovarian cancer. [Abstract]2026 May 25. PMID: 42185630 -
-
Cell Mol Biol Lett
HK2-driven histone H3K18 lactylation promotes stromal cell senescence and decidualization deficiency in URSA via CUX1-mediated SASP factor transcription. [Abstract]2026 Mar 9;31(1):31. PMID: 41803676 -
Cell Death Dis
Oncometabolite fumarate facilitates PD-L1 expression and immune evasion in clear cell renal cell carcinoma. [Abstract]2025 Jun 3;16(1):432. PMID: 40461489 -
Cell Death Dis
CBP/p300 HAT maintains the gene network critical for β cell identity and functional maturity. [Abstract]2021 May 12;12(5):476. PMID: 33980820 -
Cell Death Dis
Selective inhibition of CBP/p300 HAT by A-485 results in suppression of lipogenesis and hepatic gluconeogenesis. [Abstract]2020 Sep 11;11(9):745. PMID: 32917859 -
J Exp Med
2025 May 5;222(5):e20241184. PMID: 39969510 -
Acta Pharmacol Sin
Targeting PPARα activation sensitizes glioblastoma cells to temozolomide and reverses acquired resistance by inhibiting H3K18 lactylation. [Abstract]2025 Jun 11. PMID: 40500345 -
Cell Death Discov
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia. [Abstract]2024 May 1;10(1):206. PMID: 38693103 -
Acta Pharmacol Sin
2022 Feb;43(2):457-469. PMID: 33850273 -
Proc Natl Acad Sci U S A
2026 Mar 10;123(10):e2525274123. PMID: 41779776 -
Cell Chem Biol
2021 Apr 15;28(4):503-514.e12. PMID: 33400925 -
JHEP Rep
Spatial proteomics and cell-cell cross-talk analysis reveal PD-L1 and IL-6 interaction in human primary sclerosing cholangitis. [Abstract]2026 May 27:101903. PMID: 42208680 -
Int J Biol Macromol
KAT8-mediated MDH2 lactylation promotes renal cancer progression by enhancing mitochondrial function and stress resistance. [Abstract]2025 Aug 5;322(Pt 1):146571. PMID: 40769364 -
EMBO J
2025 Aug 20. PMID: 40836035 -
EMBO J
ATP citrate lyase controls hematopoietic stem cell fate and supports bone marrow regeneration. [Abstract]2022 Apr 19;41(8):e109463. PMID: 35229328 -
Mol Med
Epigenetic reprogramming drives endothelial dysfunction via neuropilin-1 in pulmonary hypertension. [Abstract]2025 Dec 16;31(1):336. PMID: 41402732 -
Free Radic Biol Med
Bone morphogenetic protein 4 ameliorates corneal neovascularization by inhibiting NLRP3 inflammasome activation through the promotion of CBP-mediated S100A9 acetylation. [Abstract]2025 Oct:238:430-449. PMID: 40618910 -
Free Radic Biol Med
MSC-derived exosomes alleviate oxidative stress-induced lysosomal membrane permeabilization damage in degenerated nucleus pulposus cells via promoting m6A demethylation of Nrf2. [Abstract]2025 Apr 30:S0891-5849(25)00272-2. PMID: 40316061 -
-
Cell Rep
Loss of p53 exacerbates autoimmunity by reprogramming propionyl-CoA metabolism and histone modifications in Treg cells. [Abstract]2026 Mar 15;45(3):117084. PMID: 41838722 -
Cell Rep
NAD+ sensing by PARP7 regulates the C/EBPβ-dependent transcription program during adipogenesis. [Abstract]2026 Jan 30;45(2):116929. PMID: 41621069 -
Cell Rep
TRIM65 as a key regulator of ferroptosis and glycolysis in lactate-driven renal tubular injury and diabetic kidney disease. [Abstract]2025 Jul 30;44(8):116091. PMID: 40748757 -
Cell Rep
2024 Nov 26;43(12):115015. PMID: 39602308 -
Aging Cell
2024 Nov;23(11):e14284. PMID: 39076122 -
Cell Rep
2023 Dec 13;42(12):113564. PMID: 38100350 -
Cell Rep
Interplay between protein acetylation and ubiquitination controls MCL1 protein stability. [Abstract]2021 Nov 9;37(6):109988. PMID: 34758305 -
Br J Pharmacol
Dual pharmacological targeting of coactivator-associated arginine methyltransferase 1 (CARM1) and salt inducible kinase (SIK) drives ketogenesis in both hepatocytes and mice. [Abstract]2026 Apr 29. PMID: 42055601 -
Cell Syst
Integrated time-series analysis and high-content CRISPR screening delineate the dynamics of macrophage immune regulation. [Abstract]2025 Aug 20;16(8):101346. PMID: 40782800 -
J Invest Dermatol
Targeting the Epigenome Reduces Keloid Fibroblast Cell Proliferation, Migration, and Invasion. [Abstract]2025 Feb;145(2):411-422.e7. PMID: 39009280 -
J Invest Dermatol
The p300/CBP inhibitor A485 normalizes psoriatic fibroblast gene expression in vitro and reduces psoriasis-like skin inflammation in vivo. [Abstract]2023 Mar;143(3):431-443.e19. PMID: 36174717 -
JCI Insight
p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes. [Abstract]2022 Jan 11;7(1):e141344. PMID: 34813504 -
Biochem Pharmacol
Acetylation of H3K18 activated by p300 promotes osteogenesis in human adipose-derived mesenchymal stem cells. [Abstract]2025 Jun:236:116901. PMID: 40164340 -
J Bone Miner Res
Acetyltransferases CBP/p300 control transcriptional switch of β-catenin and Stat1 promoting osteoblast differentiation. [Abstract]2023 Dec;38(12):1885-1899. PMID: 37850815 -
Liver Int
Inhibition of ACSS2 attenuates alcoholic liver steatosis via epigenetically regulating de novo lipogenesis. [Abstract]2023 Aug;43(8):1729-1740. PMID: 37183518 -
EMBO Rep
NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis. [Abstract]2025 Jun;26(12):3106-3137. PMID: 40369363 -
Stem Cells Transl Med
3D Spheroids Facilitate Differentiation of Human Adipose-Derived Mesenchymal Stem Cells into Hepatocyte-Like Cells via p300-Mediated H3K56 Acetylation. [Abstract]2024 Feb 14;13(2):151-165. PMID: 37936499 -
Commun Biol
Deoxynivalenol induces ferroptosis via inhibiting glycolysis-H3K18la-STEAP3 axis to promote ovary damage in piglets. [Abstract]2025 Nov 20;8(1):1626. PMID: 41266595 -
Int Immunopharmacol
Lactate represses MHC-I antigen presentation via H4K5 lactylation-PRC2 in small cell lung cancer subtype A. [Abstract]2026 Feb 1:170:116125. PMID: 41468795 -
Int J Mol Sci
Generation of Bona Fide Human Induced Trophoblast Stem Cells by Direct Reprogramming of Term Umbilical Cord Cells. [Abstract]2024 Dec 31;26(1):271. PMID: 39796127 -
Int J Mol Sci
2023 Apr 11;24(8):7031. PMID: 37108194 -
Int Immunopharmacol
p300/CBP inhibitor A-485 inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. [Abstract]2021 May:94:107458. PMID: 33626422 -
-
Biol Direct
PNSC928, a plant-derived compound, specifically disrupts CtBP2-p300 interaction and reduces inflammation in mice with acute respiratory distress syndrome. [Abstract]2024 Jun 21;19(1):48. PMID: 38902802 -
Biol Res
Decoding a novel non-enzymatic protein acetylation mechanism in sperm that is essential for fertilizing potential. [Abstract]2025 May 29;58(1):30. PMID: 40442844 -
Toxicology
H3K18 lactylation-mediated SIX1 upregulation contributes to silica-induced epithelial-mesenchymal transition in airway epithelial cells. [Abstract]2025 Jun:514:154109. PMID: 40049282 -
PLoS Pathog
2023 Feb 24;19(2):e1011202. PMID: 36827461 -
PLoS Pathog
Bacterial infection promotes tumorigenesis of colorectal cancer via regulating CDC42 acetylation. [Abstract]2023 Feb 22;19(2):e1011189. PMID: 36812247 -
Cancers (Basel)
CIC-DUX4 Chromatin Profiling Reveals New Epigenetic Dependencies and Actionable Therapeutic Targets in CIC-Rearranged Sarcomas. [Abstract]2024 Jan 21;16(2):457. PMID: 38275898 -
Cancers (Basel)
LncRNA LINC00518 Acts as an Oncogene in Uveal Melanoma by Regulating an RNA-Based Network. [Abstract]2020 Dec 21;12(12):3867. PMID: 33371395 -
Cell Signal
Cadmium contributes to cardiac metabolic disruption by activating endothelial HIF1A-GLUT1 axis. [Abstract]2024 Jul:119:111170. PMID: 38604344 -
Brain Res Bull
Inhibiting H3K18 lactylation in microglia aggravates white matter injury after intracerebral hemorrhage in mice. [Abstract]2026 Feb:235:111744. PMID: 41616944 -
iScience
Global isonicotinylome analysis identified SMAD3 isonicotinylation promotes liver cancer cell epithelial-mesenchymal transition and invasion. [Abstract]2024 Aug 21;27(9):110775. PMID: 39286495 -
ACS Chem Neurosci
2021 Jul 7;12(13):2273-2279. PMID: 34110772 -
BMC Cancer
Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition. [Abstract]2025 May 28;25(1):955. PMID: 40437414 -
Pathogens
2023 Jun 15;12(6):831. PMID: 37375521 -
Cancer Med
Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma. [Abstract]2026 Jun;15(6):e71985. PMID: 42231094 -
Exp Cell Res
2022 Nov 1;420(1):113336. PMID: 36058294 -
Tissue Cell
H3K27 acetylation activated-CCS regulates autophagy and apoptosis of lung cancer by alleviating oxidative stress. [Abstract]2023 Feb:80:101964. PMID: 36402120 -
Mol Biol Cell
2024 Jun 1;35(6):ar88. PMID: 38656803 -
Insects
BmCBP Catalyzes the Acetylation of BmApoLp-II Protein and Regulates Its Stability in Silkworm, Bombyx mori. [Abstract]2023 Mar 23;14(4):309. PMID: 37103124 -
Biochem Biophys Res Commun
Apigenin suppresses epithelial-mesenchymal transition in high glucose-induced retinal pigment epithelial cell by inhibiting CBP/p300-mediated histone acetylation. [Abstract]2024 Jul 12:717:150061. PMID: 38718570 -
Biochem Biophys Res Commun
Upregulation of α enolase (ENO1) crotonylation in colorectal cancer and its promoting effect on cancer cell metastasis. [Abstract]2021 Sep 16;578:77-83. PMID: 34547627 -
Biomed Chromatogr
Development and validation of a liquid chromatography-tandem mass spectrometry method for the quantification of the acetyl-coenzyme A competitive p300/CBP catalytic inhibitor A-485 in biological samples. [Abstract]2024 Apr;38(4):e5819. PMID: 38148286 -
-
bioRxiv
Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States. [Abstract]2026 May 26:2026.05.22.726988. PMID: 42244620 -
bioRxiv
2026 Apr 4:2026.04.03.716381. PMID: 41959418 -
bioRxiv
2026 Feb 13:2026.02.12.705659. PMID: 41727155 -
-
bioRxiv
Tau seeding in neurons enabled by transient endolysosomal perforations are confined within endolysosomes. [Abstract]2025 Nov 3:2025.11.02.686178. PMID: 41278722 -
bioRxiv
Short chain fatty acids regulate the chromatin landscape and distinct gene expression changes in human colorectal cancer cells. [Abstract]2025 May 13:2025.05.07.652677. PMID: 40463142 -
bioRxiv
2025 Apr 28:2025.04.28.651040. PMID: 40492193 -
Environ Toxicol
H3K27 Acetylation-Activated GLDC Accelerated the Advancement of Oral Squamous Cell Carcinoma by Suppressing the p53 Signaling Pathway. [Abstract]2025 Jan;40(1):140-151. PMID: 39415627 -
bioRxiv
The CoREST-complex regulates MYC stability and promotes post-transcriptional mRNA splicing in melanoma. [Abstract]2024 Dec 23:2024.12.23.630174. PMID: 39764010 -
-
-
-
-
Biomed Pharmacother
XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma. [Abstract]2023 Apr:160:114402. PMID: 36791564
A-485 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 Apr:160:114402. [Abstract]
A485 (1, 3 µM; 4 h) reduces endogenous acetylation of NPM1 in HA-NPM1-transfected Huh7/SR NPM1 KD cells.
-
Solvent & Solubility
DMSO : 100 mg/mL (186.40 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Cell lines are plated in 96 well or 384 well plates and allowed to adhere for 24 h. The cells are then treated with A-485 for 3, 4, or 5 days. Experiments are run in triplicate and the fraction of viable cells is determined using the Cell Viability Assay according to the manufacturer’s recommendations. For Thymidine incorporation assays, cells are treated with A-485 for 1, 2, 3, or 4 days. Twenty four hours prior to the time point, tritiated thymidine is added and cells are incubated for an additional 24 h. Genomic DNA is then isolated on filter plates[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
The LuCap-77 CR prostate PDX model is used in this study. Donor tumors are dissociated and injected as a brie (1:2) into the right flank of 16 week old male C.B.-17 SCID mice on day 0 in a volume of 0.2 mL. Tumors are size matched on day 26 post-inoculation with a mean tumor volume of 211±3 (SEM) mm3 with dosing beginning on day 28. Mice are randomized into treatment groups using Studylog software based on tumor volume. LuCap-77 CR xenograft tumors are established in SCID mice and animals are dosed with A-485 as for 7 days. Three hours post the final dose, tumors are harvested and snap frozen on dry ice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8640 mL | 9.3200 mL | 18.6400 mL | 46.6001 mL |
| 5 mM | 0.3728 mL | 1.8640 mL | 3.7280 mL | 9.3200 mL | |
| 10 mM | 0.1864 mL | 0.9320 mL | 1.8640 mL | 4.6600 mL | |
| 15 mM | 0.1243 mL | 0.6213 mL | 1.2427 mL | 3.1067 mL | |
| 20 mM | 0.0932 mL | 0.4660 mL | 0.9320 mL | 2.3300 mL | |
| 25 mM | 0.0746 mL | 0.3728 mL | 0.7456 mL | 1.8640 mL | |
| 30 mM | 0.0621 mL | 0.3107 mL | 0.6213 mL | 1.5533 mL | |
| 40 mM | 0.0466 mL | 0.2330 mL | 0.4660 mL | 1.1650 mL | |
| 50 mM | 0.0373 mL | 0.1864 mL | 0.3728 mL | 0.9320 mL | |
| 60 mM | 0.0311 mL | 0.1553 mL | 0.3107 mL | 0.7767 mL | |
| 80 mM | 0.0233 mL | 0.1165 mL | 0.2330 mL | 0.5825 mL | |
| 100 mM | 0.0186 mL | 0.0932 mL | 0.1864 mL | 0.4660 mL |